Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Inventiva S.A.
Inventiva S.A. News
Inventiva S.A. Quantitative Score
About Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Inventiva S.A. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Inventiva S.A. Financials
Table Compare
Compare IVA metrics with: | |||
|---|---|---|---|
Earnings & Growth | IVA | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | IVA | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | IVA | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | IVA | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Inventiva S.A. Income
Inventiva S.A. Balance Sheet
Inventiva S.A. Cash Flow
Inventiva S.A. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Inventiva S.A. Executives
| Name | Role |
|---|---|
| Dr. Pierre Broqua Ph.D. | Co-Founder |
| Dr. Martine Zimmermann Pharm.D. | Executive Vice President of Regulatory Affairs & Quality Assurance |
| Mr. Jean Volatier | Deputy GM & Chief Financial Officer |
| Ms. Alice Roudot-Ketelers Pharm.D. | Chief Operating Officer |
| Ms. Pascaline Clerc Ph.D. | Executive Vice President of Strategy & Corporate Affairs |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Pierre Broqua Ph.D. | Co-Founder | 1962 | 424.85K | |
| Dr. Martine Zimmermann Pharm.D. | Executive Vice President of Regulatory Affairs & Quality Assurance | 1969 | 69.13K | |
| Mr. Jean Volatier | Deputy GM & Chief Financial Officer | Male | 1965 | -- |
| Ms. Alice Roudot-Ketelers Pharm.D. | Chief Operating Officer | Female | 1971 | -- |
| Ms. Pascaline Clerc Ph.D. | Executive Vice President of Strategy & Corporate Affairs | Female | 1980 | -- |